Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-related degenerative diseases.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
Description
Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-07-18 07:00 |
Biophytis et SEQENS signent un partenariat pour la production du principe actif…
|
French | 217.1 KB | ||
| 2023-07-11 07:00 |
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE DE BIOPHYTIS
|
Portuguese | 367.2 KB | ||
| 2023-07-10 07:00 |
Biophytis a demandé à la FDA l’autorisation de lancer l’étude SARA-31 de phase …
|
French | 198.1 KB | ||
| 2023-06-19 07:00 |
Biophytis présente les résultats cliniques de Sarconeos (BIO101) dans la sarco…
|
French | 201.4 KB | ||
| 2023-06-16 23:00 |
RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE DU 16 JUIN 2023 ADOPTION DE L’ENSEMBLE DES RÉ…
|
French | 174.4 KB | ||
| 2023-06-05 08:00 |
Biophytis annonce sa participation à la BIO International Convention de Boston …
|
French | 167.3 KB | ||
| 2023-05-26 08:00 |
Biophytis a soumis à la Haute Autorité de Santé (HAS) une demande d’Autorisatio…
|
French | 211.3 KB | ||
| 2023-05-25 08:00 |
Biophytis a présenté les résultats positifs de Phase 2-3 COVA à la Conférence …
|
French | 196.2 KB | ||
| 2023-05-15 08:00 |
Biophytis a demandé à l’EMA l’autorisation de lancer l’étude SARA-31 de phase 3…
|
French | 198.3 KB | ||
| 2023-05-11 08:00 |
Succès de l’augmentation de capital de Biophytis avec 2,3 millions d’euros lev…
|
French | 338.5 KB | ||
| 2023-05-10 19:10 |
Biophytis lance une levée de fonds d’environ 2 millions d’euros
|
French | 221.1 KB | ||
| 2023-05-09 08:00 |
Biophytis a requis auprès de l’EMA une réunion de pré-soumission d’Autorisation…
|
French | 185.4 KB | ||
| 2023-05-02 08:00 |
Biophytis annonce le renforcement de son équipe de Direction
|
French | 185.5 KB | ||
| 2023-04-28 23:00 |
Biophytis reçoit une notification du Nasdaq
|
French | 190.8 KB | ||
| 2023-04-19 08:00 |
Biophytis se conforme à nouveau aux exigences du NASDAQ en matière de cours d’a…
|
French | 171.6 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biophytis S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
Peer Companies
